NMDP

Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Saving Cell Therapy

Retrieved on: 
Mercoledì, Maggio 8, 2024
NMDP, Blood, Life saver, Publicis, Bronchitis, Research, Leukemia, Patient, American Symphony, Bone marrow, Acute myeloid leukemia, Higher Ground, Cipriani S.A., AstraZeneca, Pharmaceutical industry

In 2023, NMDP provided $5.5 million in grants to 2,600 patients and their families in need of financial assistance.

Key Points: 
  • In 2023, NMDP provided $5.5 million in grants to 2,600 patients and their families in need of financial assistance.
  • The event’s presenting sponsor, Publicis Groupe and Publicis Media, continued their long-standing support of NMDP.
  • “All of us at NMDP are honored to witness meetings like Lisa and Eric’s” said Joy King, Chief Advancement Officer, NMDP.
  • The organization recently unveiled breakthrough research that will allow more patients with blood cancer or blood disorders to receive life-saving cell therapy.

Medical College of Wisconsin Cancer Center leads groundbreaking change in Medicare policy for MDS patients over 65 in need of lifesaving transplants

Retrieved on: 
Mercoledì, Maggio 8, 2024
BMT, NMDP, Transplant, MCW, National Marrow Donor Program, MD, HCT, Research, Doctor of Science, History, Syndrome, ASH, Patient, Society, Medicare, Blood, MDS, Cancer, Medical college

MDS is a group of cancers that affect the body's ability to produce healthy blood cells.

Key Points: 
  • MDS is a group of cancers that affect the body's ability to produce healthy blood cells.
  • Allogeneic HCT is the only curative therapy for patients with MDS.
  • This challenge was further exacerbated since older adults were, consequently, overlooked as candidates for transplant because they did not have Medicare coverage for the procedure.
  • A final decision was recently made by Medicare in the form of a National Coverage Analysis Decision Memo to expand Medicare coverage for the affected population.

NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Mercoledì, Aprile 24, 2024
City, NMDP, MMUD, HLA, Haematopoietic system, Hematology, Hope, HCT, Research, Associate professor, ASCO, Bone marrow, Patient, ACCESS, Society, CDT, Medical college, Dentistry

MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.

Key Points: 
  • MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.
  • A chief focus will be sharing interim findings from ACCESS, the prospective, multi-center, Phase II clinical trial of HCT using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children.
  • “New findings from the ACCESS study will advance broader understanding of how mismatched unrelated donors can safely and effectively address gaps in equitable access to transplant for those patients who are unable to find a fully matched donor,” said Steven M. Devine, M.D., Chief Medical Officer, NMDP; Senior Scientific Director, CIBMTR.
  • Presenting Author: Monzr M. Al Malki, M.D., Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
    Title: Identifying states for targeted alloHCT access initiatives using social vulnerability, physician density, and unmet need
    Full abstracts will be available at 4 p.m. CDT, May 23, 2024, on the ASCO Annual Meeting website .

CIBMTR® Launches Rapid Clinical Site Selection and Activation, Resulting in Faster Trial Enrollment for Cell and Gene Therapy Trials

Retrieved on: 
Mercoledì, Maggio 1, 2024
Research, FDA, Genetics, Clinical Trials, Health Technology, Stem Cells, Health, Other Science, Science, CRA, Clinical trial, NMDP, IRB, CGT, DSMB, Culture, Annual general meeting, Growth, Pharmaceutical industry

NMDP BioTherapies announced today that CIBMTR CRO Services now offers a rapid clinical site selection and activation service, resulting in faster trial enrollment for cell and gene therapy (CGT) trials.

Key Points: 
  • NMDP BioTherapies announced today that CIBMTR CRO Services now offers a rapid clinical site selection and activation service, resulting in faster trial enrollment for cell and gene therapy (CGT) trials.
  • By leveraging data from its 675,000+ patient clinical outcomes database, CIBMTR can quickly identify, vet and select transplant centers based on patient population, diversity and competing trials.
  • “At hand-off to our dedicated site startup team, we leverage our deep relationships with transplant centers to get your CGT trial activated and enrolling quickly, which enables sponsors to reduce the time required to launch and execute high-impact clinical trials,” notes Erin Leckrone, Vice President, Clinical Trials.
  • Content: In an era marked by increasing data complexity, this session explores foundational data oversight concepts crucial for successful clinical investigations.

NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development

Retrieved on: 
Martedì, Aprile 16, 2024
Health, Health Technology, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, RUO, CBUS, CBU, Investment, NMDP, Match, Collection, Research, KIR, Drug Master File, Cryopreservation, Patient, GMP, DMF, CD16, Organization, Medical device

NMDP BioTherapies ℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

Key Points: 
  • NMDP BioTherapies ℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.
  • “We have leveraged over three decades of experience in managing cellular product collections, working closely with cell and gene therapy developers to deliver an advanced allogeneic suite of compliant products,” said Tom Hochuli, President of NMDP BioTherapies.
  • “These investments in our cellular starting material offerings are a testament to our commitment to advancing the cell and gene therapy industry.
  • Recognizing the diverse stages of cell therapy development, NMDP BioTherapies has broadened its RUO leukopak capabilities.

NMDP Cycle Kicks Off Nationwide Cycling Events Giving Hope to Patients in Need of a Blood Stem Cell Transplant

Retrieved on: 
Venerdì, Marzo 29, 2024
Eclipse, Diagnosis, Sickle cell disease, Bone marrow, Growth, Physician, Patient, Research, Hope, Leukemia, Date, Daily, Falkenberg, NMDP

By raising funds, NMDP Cycle helps more patients access cell therapy treatments for up to 75 different blood cancers, including leukemia, or blood disorders such as sickle cell disease.

Key Points: 
  • By raising funds, NMDP Cycle helps more patients access cell therapy treatments for up to 75 different blood cancers, including leukemia, or blood disorders such as sickle cell disease.
  • "I am alive today because of the selfless act of a blood stem cell donor,” said Bob Falkenberg, founder of the NMDP cycling program.
  • He began cycling to fundraise for NMDP, would stop at transplant centers along the way, inspiring both hospital staff and patients.
  • The organization recently unveiled breakthrough research that will allow more patients with blood cancer or blood disorders to receive life-saving cell therapy.

NMDP Receives Record-Breaking $5 Million Philanthropic Gift

Retrieved on: 
Martedì, Marzo 19, 2024
Patient, Bone marrow, Research, NMDP, Pharmaceutical industry

A portion of the $5 million will fund recruitment, to continue adding young, ethnically diverse members to the NMDP Registry, the world’s most diverse registry of blood stem cell or marrow donors.

Key Points: 
  • A portion of the $5 million will fund recruitment, to continue adding young, ethnically diverse members to the NMDP Registry, the world’s most diverse registry of blood stem cell or marrow donors.
  • Another part of the gift will support patient financial assistance, the number one patient-reported barrier to transplant.
  • “With the Moore family’s generous contribution to NMDP, good goes a long way in advancing our mission, and we are extremely grateful.
  • Thanks in part to philanthropic gifts, NMDP has made monumental strides in accelerating progress and expanding access to treatment.

NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research

Retrieved on: 
Mercoledì, Marzo 6, 2024
Bone marrow, Senior, Doctor of Philosophy, HCT, Research, Hematology, Graft-versus-host disease, Physician, Partnership, Data, University, Risk assessment, NMDP, Nursing, Patient, Disease, McGinn, DRS, Health equity, Laboratory, Buchbinder, Wilfrid Sellars, Pharmaceutical industry

Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.

Key Points: 
  • Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.
  • We are especially grateful to the Moore family, who generously funded the Amy Scholars Research Program in 2024,” said Joy King, Chief Advancement Officer, NMDP, and Executive Director, NMDP.
  • Since 1998, NMDP has invested more than $12 million, funding 51 early-career investigators and helping them develop research portfolios and establish their laboratories.
  • “For years, we have supported groundbreaking research by collaborating with an extensive network of physicians and scientists in impacting outcomes.

NMDP Announces Enrollment of First Patient in OPTIMIZE Clinical Trial

Retrieved on: 
Martedì, Febbraio 20, 2024
Haematopoietic system, Incidence, Bone marrow, Senior, Infection, Toxicity, MMUD, HCT, Malignancy, Graft-versus-host disease, Quality of life, ACCESS, GVHD, Safety, NMDP, Health, Patient, OHSU, Survival, Clinical trial, Health equity, Research, Vaccine

The trial is sponsored by NMDP through the Center for International Blood and Marrow Transplant Research (CIBMTR®).

Key Points: 
  • The trial is sponsored by NMDP through the Center for International Blood and Marrow Transplant Research (CIBMTR®).
  • The OPTIMIZE trial hypothesizes that a reduced PTCy dosage could reduce these risks while still effectively guarding against GvHD.
  • The OPTIMIZE trial’s goals include:
    Improve patient survival and quality of life by decreasing acute and long-term toxicities associated with standard dose PTCy.
  • This trial recently completed enrollment in its adult arms ahead of schedule and is continuing to enroll within its pediatric arm.

NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development

Retrieved on: 
Martedì, Gennaio 30, 2024
Research, History, Match, Patient, Bone marrow, Collection, MBA, NMDP, Clarkson University, Rutgers University, Organization

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase.

Key Points: 
  • MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase.
  • NMDP BioTherapies supports organizations that are creating next-generation cell and gene therapies.
  • While NMDP BioTherapies will be a separate legal entity from NMDP with its own dedicated employee team, the organization will draw from the extensive research and resources that NMDP has to offer.
  • Hochuli will lead the team in delivering end-to-end excellence – from donor identification to therapy delivery.